Review of the effects of 17α-estradiol in humans: A less feminizing estrogen with neuroprotective potential

Drug Development Research

Volumn 70, Issue 1, 2009, Pages 1-21

  Moos, Walter H ^a,c,d   Dykens, James A ^a,e   Nohynek, Dana ^b   Rubinchik, Evelina ^b   Howell, Neil ^a  

^a MIGENIX   (United States)

^b MIGENIX   (Canada)

^c SRI INTERNATIONAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

17 estradiol; 17 estradiol; Alzheimer's disease; Estradiol; Estrogen; Friedreich's ataxia; Hormone replacement therapy; Human studies; Huntington's disease; Mitochondria; Neuroprotection; Parkinson's disease; Phase I clinical trial; Premarin7 ; Retinitis pigmentosa; Stroke; Women's health initiative

Indexed keywords

17ALPHA ESTRADIOL; ABP 150; CERULOPLASMIN; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CREATININE; EQUILENIN; EQUILIN; ESTRADIOL; ESTRATEST; ESTRIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE; ESTRONE SULFATE; FINASTERIDE; GROWTH HORMONE; GYNODIOL; INSULIN; LOW DENSITY LIPOPROTEIN; MITO 4565; MX 4565; NITRIC OXIDE; PANTOSTIN; PLACEBO; PREFEST; PROLACTIN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE DIPHOSPHATE GLUCOSE; ZYC 5;

ALOPECIA; ALZHEIMER DISEASE; AREA UNDER THE CURVE; BIOAVAILABILITY; BIOEQUIVALENCE; BLOOD PRESSURE; BODY TEMPERATURE; BODY TEMPERATURE SENSATION; BODY WEIGHT; BRAIN MITOCHONDRION; BREAST TENDERNESS; BREATHING RATE; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG EXCRETION; DRUG MARKETING; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; EDEMA; ESTRADIOL BLOOD LEVEL; ESTRIOL BLOOD LEVEL; ESTROGEN METABOLISM; ESTROGEN THERAPY; ESTRONE BLOOD LEVEL; FEMINIZATION; FOOD AND DRUG ADMINISTRATION; FOOD COMPOSITION; GYNECOMASTIA; HEADACHE; HUMAN; LIBIDO DISORDER; LIPID OXIDATION; MAXIMUM PLASMA CONCENTRATION; MEAT; MENSTRUAL CYCLE; NAUSEA; NEUROPROTECTION; PARKINSON DISEASE; REVIEW; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TINGLING; TABLET FORMULATION; TESTOSTERONE METABOLISM; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; UTERINE CERVIX MUCUS; VAGINA BLEEDING; VAGINA SMEAR;

EID: 61349156673     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20284     Document Type: Review

References (112)

1. Adams JB, McDonald D. 1981. Enzymic synthesis of steroid sulphates. XIV. Properties of human adrenal steroid alcohol sulphotransferase. Biochim Biophys Acta 664:460-468.
2. Adams WP, Hasegawa J, Johnson RN, Haring RC. 1979. Conjugated estrogens bioinequivalence: comparison of four products in postmenopausal women. J Pharm Sci 68:986-991.
3. Adlercreutz H, Luukkainen T. 1969. Studies on estrogen metabolism in the adult human organism in vivo. In: Raspé G, editor. Advances in the Biosciences. Oxford: Pergamon. Vol 3. p 53-70.
4. Adlercreutz H, Luukkainen T. 1970. Identification and determination of oestrogens in various biological materials in pregnancy. Ann Clin Res 2:365-380.
5. Baumgartner AR. 1999. Probing Premarin. Can Med Assoc J 161:1390.
6. Behl C. 2005. Oxidative stress in Alzheimer's disease: implications for prevention and therapy. Subcell Biochem 38:65-78.
7. Belfroid AC, Van der Horst A, Vethaak AD, Schäfer AJ, Rijs GBJ, Wegener J, Cofino WP. 1999. Analysis and occurrence of estrogenic hormone and their glucuronides in surface water and waste water in The Netherlands. Sci Total Environ 225:101-108.
8. Bhavnani BR. 1998. Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism. PSEBM 217:8-16.
9. Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN. 1999. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients. Neurology 53:91-95.
10. Bluming AZ. 2004. Hormone replacement therapy: the debate should continue. Geriatrics 59:30-37.
11. Breuer H, Schott E. 1966. Studies on the metabolism of 17α-estradiol in man. J Clin Endocrinol 26:533-536.
12. Brinton RD. 2004. Requirements of a brain selective estrogen: advances and remaining challenges for developing a Neuro-SERM. J Alzheimer Dis 6(Suppl):S27-S35.
13. Cegelski L, Rice CV, O'Connor RD, Caruano AL, Tochtrop GP, Cai ZY, Covey DF, Schaefer J. 2006. Mapping the locations of estradiol and potent neuroprotective analogues in phospholipids bilayers by REDOR. Drug Dev Res 66:93-102.
14. Chakrabarti E, Wang J, Claire-Olsen J, Smith JD. 2005. Lack of protective effect of estrogens on cerebral Aβ levels in intact female and male APP transgenic mice. Drug Dev Res 66:136-141.
15. Chen J-Q, Russo PA, Cooke C, Russo IH, Russo J. 2007. ERβ shifts from mitochondria to nucleus during estrogen-induced neoplastic transformation of human breast epithelial cells and is involved in nitrogen-induced synthesis of mitochondrial respiratory chain proteins. Biochim Biophys Acta 1773:1732-1746.
16. Chiasson K, Lahaie-Collins V, Bournival J, Delapierre B, Gélinas S, Martinoli MG. 2006. Oxidative stress and 17-alpha- and 17-beta-estradiol modulate neurofilaments differently. J Mol Neurosci 30:297-310.
17. Cordey M, Gundimeda U, Gopalakrishna R, Pike CJ. 2005. The synthetic estrogen 4-estren-3 alpha, 17 beta-diol (estren) induces estrogen-like neuroprotection. Neurobiol Dis 19:331-339.
18. Dey M, Lyttle CR, Picar JH. 2000. Recent insights into the varying activity of estrogens. Maturitas 34:S25-S33.
19. Dominguez R, Liu R, Baudry M. 2007. 17-β-estradiol-mediated activation of extracellular-signal regulated kinase, phosphatidylinositol 3-kinase/protein kinase B-Akt and N-methyl-D-aspartate receptor phosphorylation in cortical synaptoneurosomes. J Neurochem 101:232-240.
20. Dykens JA. 2007. Redox enzymes. In: Taylor JB, Triggle DJ, Moos WH, editors. Comprehensive medicinal chemistry. II. 2nd ed. Oxford: Elsevier. Vol 2. p 1053-1087.
21. Dykens JA, Simpkins JW, Wang J, Gordon K. 2003. Polycyclic phenols, estrogens and neuroprotection: a proposed mitochondrial mechanism. Exp Gerontol 38:101-107.
22. Dykens JA, Moos WH, Howell N. 2005a. Development of 17α-estradiol as a neuroprotective therapeutic agent. Rationale and results from a Phase I clinical study. Ann NY Acad Sci 1052:116-135.
23. Dykens JA, Wersinger C, Sidhu A. 2005b. 17β- and 17α-estradiol are non-competitive inhibitors of dopamine uptake: implications for Parkinson's disease models and therapeutics. Drug Dev Res 66:160-171.
24. Fotherby K. 1996. Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception 54:59-69.
25. Gerhardt K, Ludwig-Köhn, Henning HV, Remberg G, Zeeck A. 1989. Identification of oestrogen metabolites in human urine by capillary gas chromatography and mass spectrometry. Biomed Environ Mass Spect 18:87-95.
26. Grady D. 2003. Postmenopausal hormones-therapy for symptoms only. N Engl J Med 348:1835-1837.
27. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. 2002. Production and actions of estrogens. JAMA 346:340-352.
28. Harman SM, Brinton SA, Clarkson T, Heward CB, Hecht HS, Karas RH, Judelson DR, Naftolin F. 2004. Is the WHI relevant to HRT started in the perimenopause?. Endocrine 24:195-202.
29. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N. 2005a. KEEPS: the Kronos early estrogen prevention study. Climacteric 8:3-12.
30. Harman SM, Naftolin F, Brinton EA, Judelson DR. 2005b. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann NY Acad Sci 1052:43-56.
31. Hart JE. 1990. Endocrine pathology of estrogens. Species differences. Pharmacol Ther 47:203-218.
32. Hart SA, Snyder MA, Smejkalova T, Woolley CS. 2007. Estrogen mobilizes a subset of estrogen receptor-α-immunoreactive vesicles in inhibitory presynaptic boutons in hippocampal CA1. J Neurosci 27:2102-2111.
33. Hartmann S, Lacorn M, Steinhard H. 1998. Natural occurrence of steroid hormones in food. Food Chem 62:7-20.
34. Heywood R, Wadsworth PF. 1980. The experimental toxicology of estrogens. Pharmacol Ther 8:125-142.
35. Hobe G, Schon R, Goncharov N, Katsiya G, Koryakin M, Gesson-Cholat I, Oettel M, Zimmermann H. 2002. Some new aspects of 17α-estradiol metabolism in man. Steroids 67:883-893.
36. Honjo H, Iwasa K, Kawata M, Fushiki S, Hosoda T, Tatsumi H, Oida N, Mihara M, Hirasuoi Y, Yamamoto H, Kikuchi N, Kitawaki J. 2005. Progestins and estrogens and Alzheimer's disease. J Steroid Biochem Mol Biol 93:305-308.
37. Howell N, Dykens J, Moos WH. 2005a. Alzheimer's disease, estrogens, and clinical trials: a case study in drug development for complex disorders. Drug Dev Res 66:53-77.
38. Howell N, Dykens J, Moos WH. 2005b. Estrogens and neuroprotection: desperate housewives, lost, and survivor. Drug Dev Res 66:51-52.
39. Jelks KB, Wylie R, Floyd CL, McAllister AK, Wise P. 2007. Estradiol targets synaptic proteins to induce glutamatergic synapse formation in cultured hippocampal neurons: critical role of estrogen receptor-α. J Neurosci 27:6903-6913.
40. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson J-A. 1997. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138:863-870.
41. Kuiper GGJM, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson J-A. 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139:4252-4263.
42. Kuhnz W, Gansau C, Mahler M. 1993. Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17β-estradiol. Arzneim Forsch Drug Res 43:966-973.
43. Lauritzen C. 1969. Oestrogenaktivität von 17α-oestradiol, equilin, equilenin und ihren sulfokonjugaten im tierversuch und beim menschen. Symp Dtsch Gesell Endokrinol 15:142-144.
44. Levin-Allerhand JA, Lominska CE, Wang J, Smith JD. 2002. 17α-estradiol and 17β-estradiol treatments are effective in lowering cerebral amyloid-β levels in AβPPSWE transgenic mice. J Alzheimer Dis 4:449-457.
45. 5 adrenal steroids. Endocrinology 127:2757-2762.
46. Luukkainen T, Adlercreutz H. 1965. Isolation and identification of 11-dehydro-estradiol-17α, a new type of urinary steroid, in the urine of pregnant women. Biochim Biophys Acta 107:579-592.
47. Maki PM. 2004. Hormone therapy and risk for dementia: where do we go from here? Gynecol Endocrinol 19:354-359.
48. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, Kuller LH, Cochrane BB, Hunt JR, Ludlam SE, Pettinger MB, Gass M, Margolis KL, Nathan L, Ockene JK, Prentice RL, Robbins J, Stefanick ML. 2007. Estrogen therapy and coronary-artery calcification. N Engl J Med 356:2591-2602.
49. Maume D, Deceuninck Y, Pouponneau K, Paris A, Le Bizec B, Andre F. 2001. Assessment of estradiol and its metabolites in meat. APMIS 109:32-38.
50. Mendelsohn ME, Karas RH. 2007. HRT and the young at heart. N Engl J Med 356:2639-2641.
51. Merchenthaler I, Shughrue PJ. 2005. Neuroprotection by estrogen in animal models of ischemia and Parkinson's disease. Drug Dev Res 66:172-181.
52. Meyer III WJ, Henneman DH, Keiser HR, Bartter FC. 1976. 17α Estradiol: separation of estrogen effect on collagen from other clinical and biochemical effects in man. Res Commun Chem Pathol Pharmacol 13:685-695.
53. Milner TA, Lubbers LS, Alves SE, McEwen BS. 2008. Nuclear and extranuclear estrogen binding sites in the rat forebrain and autonomic medullary areas. Endocrinology 149:3306-3312.
54. Mitka M. 2007. A change of heart guidelines for women. JAMA 297:1421-1422.
55. Moos WH, Dykens JA, Howell N. 2008. 17α-Estradiol: a less-feminizing estrogen. Drug Dev Res 69:177-184.
56. Morales LBJ, Loo KK, Liu H-B, Peterson C, Tiwari-Woodruff S, Voskuhl RR. 2006. Treatment with an estrogen receptor α ligand is neuroprotective in experimental autoimmune encephalomyelitis. J Neurosci 26:6823-6833.
57. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ. 2000. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 283:1007-1015.
58. Munster U, Hammer S, Blume-Peytavi U, Schafer-Korting M. 2003. Testosterone metabolism in human skin cells in vitro and its interaction with estradiol and dutasteride. Skin Pharmacol Appl Skin Physiol 16:356-366.
59. Naftolin F, Taylor H, Karas R, Brinton E, Newman I, Clarkson T, Mendelsohn M, Lobo R, Judelson D, Nachtigall L. 2003. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 81:1498-1501.
60. Niiyama S, Happle R, Hoffmann R. 2001. Influence of estrogens on the androgen metabolism in different subunits of human hair follicles. Eur J Dermatol 11:195-198.
61. Nilsen J, Chen S, Irwin RW, Iwamoto S, Brinton RD. 2006. Estrogen protects neuronal cells from amyloid beta-induced apoptosis via regulation of mitochondrial proteins and function. BMC Neurosci 7:74.
62. Norman AW, Mizwicki MT, Norman DPG. 2004. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Disc 3:27-41.
63. Oettel M. 1999. Estrogens and antiestrogens in the male. In: Oettel M, Schillinger E, editors. Estrogens and antiestrogens. II. Pharmacology and clinical application of estrogens and antiestrogens. Berlin: Springer. p 505-571.
64. O'Neill K, Chen S, Brinton RD. 2004. Impact of the selective estrogen receptor modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer's disease. Exp Neurol 188:268-278.
65. Orfanos CE, Vogels L. 1980. Local therapy of androgenetic alopecia with 17α-estradiol. A controlled, randomized double-blind study. Dermatologica 161:124-132.
66. 3H-estradiol-17β treated veal calves. Residues Vet Drugs Food Proc EuroResidue Conf 2nd 2:518-2:522.
67. Parker-Pope T. 2007. How NIH misread hormone study in 2002. WSJ 9:B1.
68. Perez E, Liu R, Yang SH, Cai ZY, Covey DF, Simpkins JW. 2005. Neuroprotective effects of an estratriene analog are estrogen receptor independent in vitro and in vivo. Brain Res 1038:216-222.
69. Perez E, Cai ZY, Covey DF, Simpkins JW. 2006. Neuroprotective effects of estratriene analogs: structure-activity relationships and molecular optimization. Drug Dev Res 66:78-92.
70. Peri A, Danza G, Serio M. 2005. Seladin-1 as a target of estrogen receptor activation in the brain: a new gene for a rather old story? J Endocrinol Invest 28:285-293.
71. Physician's Desk Reference (PDR). 2006. 60th ed. Montvale, NJ: Thomson.
72. Prokai L, Prokai-Tatrai K, Perjési P, Simpkins JW. 2005. Mechanistic insights into the direct antioxidant effects of estrogens. Drug Dev Res 66:118-125.
73. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass MLS, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D. 2003. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289:2663-2672.
74. Rodriguez LAG, Egan K, FitzGerald GA. 2007. Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction? PLoS Med 4:822-827.
75. Roos RW, Lau-Cam CA. 1985. Liquid chromatographic analysis of conjugated esterified estrogens in tablets. J Pharmacol Sci 74:201-204.
76. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. 2007. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297:1465-1477.
77. Ruder HJ, Loriaux L, Lipsett MB. 1972. Estrone sulfate: production rate and metabolism in man. J Clin Invest 51:1020-1033.
78. Schott EW, Katzman PA. 1964. Separation and estimation of 17α-estradiol. Endocrinology 74:870-877.
79. Schriefers H, Wright MC, Rozman T, Hevert F. 1991. Inhibition of testosterone metabolism by 17-alpha-estradiol in rat liver slices. Arzneim Forsch 41:1186-1189.
80. Schröder J, Kaufmann G, Oettel M, Römer W, Sobek L. 1997. Estradiol-17α-A reasonable hormone replacement for the aging male? Maturitas 27(Suppl):216.
81. Shintani T, Klionsky DJ. 2004. Autophagy in health and disease: a double-edged sword. Science 306:990-995.
82. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones III BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J. 2003. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289:2651-2662.
83. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH. 2004. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291:2947-2958.
84. Sicotte NL, Liva SM, Klutch R, Pfieffer P, Bouvier S, Odesa S, Wu TCJ, Voskuhl RR. 2002. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 52:421-428.
85. Simpkins JW, Yang SH, Wen Y, Singh M. 2005. Estrogens, progestins, menopause and neurodegeneration: basic and clinical studies. Cell Mol Life Sci 62:271-280.
86. Singh M, Dykens JA, Simpkins JW. 2006. Novel mechanisms for estrogen-induced neuroprotection. Exp Biol Med 231:514-521.
87. Stamler J, Pick R, Katz LN, Pick A, Kaplan BM, Berkson DM, Century D. 1963. Effectiveness of estrogens for therapy of myocardial infarction in middle-age men. JAMA 183:632-638.
88. Stern MD. 1982. Pharmacology of conjugated oestrogens. Maturitas 4:333-339.
89. Stevens RE, Roy R, Phelps KV. 2002. Evaluation of single- and multiple-dose pharmacokinetics of synthetic conjugated estrogens, A (Cenestin) tablets: a slow-release estrogen replacement product. J Clin Pharmacol 42:332-341.
90. Suzuki S, Brown CM, Dela Cruz CD, Yang E, Bridwell DA, Wise PM. 2007. Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and anti-inflammatory actions. Proc Natl Acad Sci USA 104:6013-6018.
91. Toran-Allerand CD, Guan X, MacLusky NJ, Horvath TL, Diano S, Singh M, Connolly Jr ES, Nethrapalli IS, Tinnikov AA. 2002. ER-X: a novel plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J Neurosci 22:8391-8401.
92. Toran-Allerand CD, Tinnikov AA, Singh RJ, Nethrapalli IS. 2005. 17α-Estradiol: a brain-active estrogen? Endocrinology 146:3843-3850.
93. U.S. Congress, Office of Technology Assessment (OTA). 1992. The menopause, hormone therapy, and women's health. Washington, DC: U.S. Government Printing Office (May 1992, OTA-BP-BA-88).
94. United States Pharmacopeia (USP). 1982. United States Pharmacopeial Convention. 23rd revision. Rockville, MD. USP XXIII.
95. Vasudevan N, Pfaff DW. 2007. Membrane-initiated actions of estrogens in neuroendocrinology: emerging principles. Endocrine Rev 28:1-19.
96. Vegeto E, Belcredito S, Ghisletti S, Meda C, Etteri S, Maggi A. 2006. The endogenous estrogen status regulates microglia reactivity in animal models of neuroinflammation. Endocrinology 147:2263-2272.
97. Viña J, Lioret A, Vallés SL, Borrás C, Badía MC, Pallardó FV, Sastre J, Alonso MD. 2007. Mitochondrial oxidant signaling in Alzheimer's disease. J Alzheimer Dis 11:175-181.
98. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ. 2003. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA 289:2673-2684.
99. Westerholm B. 1980. Clinical toxicology of estrogens. Pharmacol Ther 10:337-349.
100. Wickelgren I. 2003. Estrogen research: brain researchers try to salvage estrogen treatments. Science 302:1138-1139.
101. 3H by nonpregnant women. J Clin Endocrinol 27:159-164.
102. Williamson DG, Layne DS. 1971. Formation of 17 alpha-estradiol-17-beta-D- glucoside by human liver homogenates. J Clin Endocrinol Metab 33:157-190.
103. 3H)estradiol-17-glucoside in normal women. Can J Biochem 50:958-962.
104. Woolley CS. 2007. Acute effects of estrogen on neuronal physiology. Annu Rev Pharmacol Toxicol 47:657-680.
105. 2+ influx via L-type calcium channels activates the src/cyclic-AMP response element binding protein signal pathway and bcl-2 expression in rat hippocampal neurons: a potential initiation mechanism for estrogen-induced neuroprotection. Neuroscience 135:59-72.
106. Xia S, Cai ZY, Thio LL, Kim-Han JS, Dugan LL, Covey DF, Rothman SM. 2002. The estrogen receptor is not essential for all estrogen neuroprotection: new evidence from a new analog. Neurobiol Dis 9:282-293.
107. Yager JD, Chen JQ. 2007. Mitochondrial estrogen receptors: new insights into specific functions. Trends Endocrinol Metab 18:89-91.
108. Yang S-H, Liu R, Perez EJ, Wen Y, Stevens Jr SM, Valencia T, Brun-Zinkernagel A-M, Prokai L, Will Y, Dykens J, Koulen P, Simpkins JW. 2004. Mitochondrial localization of estrogen receptor β. Proc Natl Acad Sci USA 101:4130-4135.
109. Yang S-H, Shi J, Day AL, Simpkins JW. 2000. Estradiol exerts neuroprotective effects when administered after ischemic insult. Stroke 31:745-750.
110. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JCS. 2002. Hormone replacement therapy and incidence of Alzheimer disease in older women. The Cache County study. JAMA 288:2123-2129.
111. Zhao L, Brinton RD. 2005. Estrogen receptor β as a therapeutic target for promoting neurogenesis and preventing neurodegeneration. Drug Dev Res 66:103-117.
112. Zhao L, Brinton RD. 2006. Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease. BMC Neurosci 7:24.